News Author: Neil Osterweil Publish date: November 14, 2018
Overly zealous editing of messenger RNA in multiple myeloma (MM) cells contributes to MM pathogenesis and is associated with poor outcomes after certa...
News Author: Neil Osterweil Publish date: November 13, 2018
MUNICH – Analyses of STAMPEDE trial data using risk criteria from two other trials revealed distinct survival benefits with abiraterone, ADT, and p...
News Author: Neil Osterweil Publish date: November 13, 2018
BOSTON—A blood management program for patients undergoing hematopoietic stem cell transplant (HSCT) can reduce inappropriate transfusions and costs wi...
News Author: Neil Osterweil Publish date: November 12, 2018
BOSTON – Blood-product use declined, with no negative effects on patients outcomes, following the start of a patient blood management program.
News Author: Neil Osterweil Publish date: November 9, 2018
MUNICH – Patients with MET exon 14–skipping mutations, but not MET gene amplification, had a high response rate to capmatinib.
News Author: Neil Osterweil Publish date: November 8, 2018
Hyper-editing of the multiple myeloma transcriptome leads to crippling of a key DNA-repair mechanism.
News Author: Neil Osterweil Publish date: November 6, 2018
New research suggests relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplant (HSCT) is related to changes in i...
News Author: Neil Osterweil Publish date: November 5, 2018
The combination was associated with good response rates in patients aged 75 years and older and those with poor-risk cytogenetics.
News Author: Neil Osterweil Publish date: November 2, 2018
Epigenetic changes that weaken the immune response appear to allow leukemic cells to escape surveillance after stem cell transplant for AML.
News Author: Neil Osterweil Publish date: November 1, 2018
MUNICH – Pembrolizumab was associated with longer overall survival and more durable responses than was cetuximab-based chemotherapy.
News Author: Neil Osterweil Publish date: October 31, 2018
MUNICH – Four-year data from the Checkmate 067 study bolster earlier findings supporting the checkpoint inhibitor combination in first line treatme...
News Author: Neil Osterweil Publish date: October 31, 2018
BOSTON—Rapid bacterial testing of platelets in a hospital blood bank can result in both significant cost savings and reduced wastage of blood products...
News Author: Neil Osterweil Publish date: October 30, 2018
BOSTON – Annual costs savings approached $89,000 and fewer units of platelets were discarded because of expiration.
News Author: Neil Osterweil Publish date: October 30, 2018
Toxicities were similar, but overall survival and disease control in patients with HPV-positive low-risk cancer was worse with cetuximab versus cis...
News Author: Neil Osterweil Publish date: October 23, 2018
MUNICH – The selective PI3K inhibitor added to fulvestrant extended progression-free survival in breast cancer patients with PIK3CA mutations.
